Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Receives $1.9M NCI Phase II Grant for Validating GeneXpert Platform

NEW YORK, May 24 (GenomeWeb News) - Cepheid has received a $1.9 million grant from the National Cancer Institute to validate its quantitative PCR-based platform for detecting tumor markers, the company said today.


Under the two-year phase II grant, scientists from Cepheid, the University of Pittsburgh Medical Center, and the Medical University of South Carolina will test and validate Cepheid's GeneXpert platform, which is based on quantitative reverse transcription PCR, for studying breast cancer and melanoma. The researchers will use the system to detect RNA from cancer cells in lymph node cross sections.


Cepheid will receive approximately $900,000 for the first year of the grant.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.